Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacquelyn Court

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Research|August 3, 2007
Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2Aled Clayton, J Paul Mitchell, Jacquelyn Court, et al.
European Journal of Immunology|March 21, 2003
Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59Aled Clayton, Claire L Harris, Jacquelyn Court, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
Human tumor-derived exosomes down-modulate NKG2D expressionAled Clayton, J Paul Mitchell, Jacquelyn Court, et al.
Journal of Translational Medicine|January 14, 2009
Can urinary exosomes act as treatment response markers in prostate cancer?Paul J Mitchell, Joanne Welton, John Staffurth, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Research|August 3, 2007
Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2Aled Clayton, J Paul Mitchell, Jacquelyn Court, et al.
European Journal of Immunology|March 21, 2003
Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59Aled Clayton, Claire L Harris, Jacquelyn Court, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
Human tumor-derived exosomes down-modulate NKG2D expressionAled Clayton, J Paul Mitchell, Jacquelyn Court, et al.
Journal of Translational Medicine|January 14, 2009
Can urinary exosomes act as treatment response markers in prostate cancer?Paul J Mitchell, Joanne Welton, John Staffurth, et al.
Pageof 1